AUSTRALIAN GROUP ON ANTIMICROBIAL RESISTANCE HOSPITAL-ONSET STAPHYLOCOCCUS AUREUS SURVEILLANCE PROGRAMME ANNUAL REPORT, 2011

被引:0
作者
Coombs, Geoffrey W. [1 ,2 ]
Nimmo, Graeme R. [3 ]
Pearson, Julie C. [1 ,2 ]
Collignon, Peter J. [4 ,5 ]
Bell, Jan M. [6 ]
McLaws, Mary-Louise [7 ]
Christiansen, Keryn J. [1 ,2 ]
Turnidge, John D. [6 ]
机构
[1] Curtin Univ, ACCESS Typing & Res, Sch Biomed Sci, Perth, WA 8000, Australia
[2] Royal Perth Hosp, Dept Microbiol & Infect Dis, PathWest Lab Med, Perth, WA, Australia
[3] Herston Hosp Campus, Div Microbiol, Pathol Queensland Cent Lab, Herston, Qld, Australia
[4] Canberra Hosp, Infect Dis Unit, Canberra, ACT, Australia
[5] Canberra Hosp, Dept Microbiol, Canberra, ACT, Australia
[6] Womens & Childrens Hosp, Dept Microbiol & Infect Dis SA Pathol, Adelaide, SA, Australia
[7] Univ New South Wales, Healthcare Associated Infect & Infect Dis Control, Sydney, NSW, Australia
关键词
antimicrobial resistance; surveillance; Staphylococcus aureus; hospital-onset infections; methicillin susceptible; methicillin resistant;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In 2011, the Australian Group on Antimicrobial Resistance (AGAR) conducted a period-prevalence survey of clinical Staphylococcus aureus isolated from hospital inpatients. Twenty-nine microbiology laboratories from all states and mainland territories participated. Specimens were collected more than 48 hours post-admission. Isolates were tested by Vitek2 (R) antimicrobial susceptibility card (AST-P612 card). Nationally, the proportion of S. aureus that were methicillin-resistant S. aureus (MRSA) was 30.3%; ranging from 19.9% in Western Australia to 36.8% in New South Wales/Australian Capital Territory. Resistance to the non-beta-lactam antimicrobials was common except for rifampicin, fusidic acid, high-level mupirocin and daptomycin. No resistance was detected for vancomycin, teicoplanin or linezolid. Antibiotic resistance in methicillin susceptible S. aureus (MSSA) was rare apart from erythromycin (13.2%) and there was no resistance to vancomycin, teicoplanin or linezolid. Inducible clindamycin resistance was the norm for erythromycin resistant, clindamycin intermediate/susceptible S. aureus in Australia with 90.6% of MRSA and 83.1% of MSSA with this phenotype having a positive double disc diffusion test (D-test). The proportion of S. aureus characterised as being healthcare-associated MRSA (HA-MRSA) was 18.2%, ranging from 4.5% in Western Australia to 28.0% in New South Wales/Australian Capital Territory. Four HA-MRSA clones were characterised and 98.8% of HA-MRSA isolates were classified as either ST22-IV [2B] (EMRSA-15) or ST239-III [3A] (Aus-2/3 EMRSA). Multiclonal community-associated MRSA (CA-MRSA) accounted for 11.7% of all S. aureus. In Australia, regional variation in resistance is due to the differential distribution of MRSA clones between regions, particularly for the major HA-MRSA clone, ST239-III [3A] (Aus-2/3 EMRSA), which is resistant to multiple non-beta-lactam antimicrobials.
引用
收藏
页码:E210 / E218
页数:9
相关论文
共 50 条
  • [31] ANNUAL REPORT OF THE AUSTRALIAN GONOCOCCAL SURVEILLANCE PROGRAMME, 2007
    Bates, John
    Murphy, Denise
    Hicks, Vicki
    Limnios, Athena
    Ray, Sanghamitra
    Shultz, Tiffany
    Lam, Anne
    Tapsall, John
    Griffith, Julia
    Bek, Mark
    Hogg, Geoff
    Weaver, Ann
    Pearson, Julie
    Tan, Hui-Leen
    Gardam, Mark
    Macgregor, Alistair
    Lum, Gary
    Southwell, Paul
    Bradbury, Susan
    Collignon, Peter
    COMMUNICABLE DISEASES INTELLIGENCE, 2008, 32 (02) : 227 - 231
  • [32] ANNUAL REPORT OF THE AUSTRALIAN GONOCOCCAL SURVEILLANCE PROGRAMME, 2006
    Bates, John
    Murphy, Denise
    Hicks, Vicki
    Limnios, Athena
    Ray, Sanghamitra
    Shultz, Tiffany
    Lam, Anne
    Tapsall, John
    Griffith, Julia
    Veitch, Mark
    Hogg, Geoff
    Weaver, Ann
    Pearson, Julie
    Gardam, Mark
    Macgregor, Alistair
    Lum, Gary
    Bradbury, Susan
    Collignon, Peter
    COMMUNICABLE DISEASES INTELLIGENCE, 2007, 31 (02) : 180 - 184
  • [33] Australian Meningococcal Surveillance Programme Annual Report, 2022
    Lahra, Monica M.
    George, Robert
    Hal, Sebastiaan J. van
    COMMUNICABLE DISEASES INTELLIGENCE, 2023, 47
  • [34] Australian Gonococcal Surveillance Programme annual report, 2010
    Lahra, Monica M.
    COMMUNICABLE DISEASES INTELLIGENCE, 2011, 35 (03) : 229 - 236
  • [35] Australian Gonococcal Surveillance Programme Annual Report, 2016
    Lahra, Monica M.
    Enriquez, Rodney
    COMMUNICABLE DISEASES INTELLIGENCE, 2018, 42
  • [36] Annual report of the Australian Gonococcal Surveillance Programme, 2005
    Tapsall, John
    COMMUNICABLE DISEASES INTELLIGENCE, 2006, 30 (02) : 205 - 210
  • [37] Australian Gonococcal Surveillance Programme Annual Report, 2020
    Lahra, Monica M.
    Hogan, Tiffany R.
    Shoushtari, Masoud
    Armstrong, Benjamin H.
    COMMUNICABLE DISEASES INTELLIGENCE, 2021, 45
  • [38] ANNUAL REPORT OF THE AUSTRALIAN GONOCOCCAL SURVEILLANCE PROGRAMME, 2009
    Lahra, Monica
    Tapsall, John
    COMMUNICABLE DISEASES INTELLIGENCE, 2010, 34 (02) : 89 - 95
  • [39] A Major Reduction in Hospital-Onset Staphylococcus aureus Bacteremia in Australia-12 Years of Progress: An Observational Study
    Mitchell, Brett G.
    Collignon, Peter J.
    McCann, Rebecca
    Wilkinson, Irene J.
    Wells, Anne
    CLINICAL INFECTIOUS DISEASES, 2014, 59 (07) : 969 - 975
  • [40] Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000
    Cantón, R
    Loza, E
    Morosini, MI
    Baquero, F
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 : 9 - 24